Skip to main content
HairCited
Figure 2

Description

Results from a phase III randomized controlled trial compare the efficacy of topical finasteride spray versus placebo in men with androgenetic alopecia. The data indicate changes in hair count or density over the treatment period, with topical finasteride associated with reduced systemic exposure relative to the oral formulation.

More Figures from This Paper

The finasteride 0.25% topical spray applicator and its mode of administration on the scalp are depicted. Developed to minimize systemic exposure compared with oral finasteride, the spray formulation targets hair follicles directly for treatment of male androgenetic alopecia.

Figure 1

The finasteride 0.25% topical spray applicator and its mode of administration on the scalp are depicted. Developed to minimize systemic exposure compared with oral finasteride, the spray formulation targets hair follicles directly for treatment of male androgenetic alopecia.

photograph

Figure 2

Chart
454 × 381px · 153,8 Kio

Source Paper

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.

Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

PMID: 34634163

DOI: 10.1111/jdv.17738

Cite This Figure

![Figure 2: Results from a phase III randomized controlled trial compare the efficacy of topical finasteride spray versus placebo in men with androgenetic alopecia. The data indicate changes in hair count or density over the treatment period, with topical finasteride associated with reduced systemic exposure relative to the oral formulation.](https://pdfs.citedhealth.com/figures/34634163/206.png)

> Source: B M Piraccini et al. "Efficacy and safety of topical finasteride spray solution for male androgenetic ." *Journal of the European Academy of Dermatology and Venereology : JEADV*, 2022. PMID: [34634163](https://pubmed.ncbi.nlm.nih.gov/34634163/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/34634163/206.png" alt="Results from a phase III randomized controlled trial compare the efficacy of topical finasteride spray versus placebo in men with androgenetic alopecia. The data indicate changes in hair count or density over the treatment period, with topical finasteride associated with reduced systemic exposure relative to the oral formulation." />
  <figcaption>Figure 2. Results from a phase III randomized controlled trial compare the efficacy of topical finasteride spray versus placebo in men with androgenetic alopecia. The data indicate changes in hair count or density over the treatment period, with topical finasteride associated with reduced systemic exposure relative to the oral formulation.<br>  Source: B M Piraccini et al. "Efficacy and safety of topical finasteride spray solution for male androgenetic ." <em>Journal of the European Academy of Dermatology and Venereology : JEADV</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34634163/">34634163</a></figcaption>
</figure>

Preuves associées

A
Finasteride pour Alopécie Androgénétique

Note A · 206 études